Exenatide once-weekly (long-acting release) showed superior HbA1c reduction and comparable weight loss to twice-daily with improved patient convenience — advancing toward the weekly injection paradigm for GLP-1 drugs.
Key findingExenatide once-weekly (long-acting release) showed superior HbA1c reduction and comparable weight loss to twice-daily with improved patient convenienc
What the researchers found
Exenatide once-weekly (long-acting release) showed superior HbA1c reduction and comparable weight loss to twice-daily with improved patient convenience — advancing toward the weekly injection paradigm for GLP-1 drugs.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2011.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.
Postgraduate medicine, 123(5), 228-38
Citation
Aroda, Vanita R; DeYoung, Mary Beth. (2011). Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.. Postgraduate medicine, 123(5), 228-38. https://doi.org/10.3810/pgm.2011.09.2479